Antiviral activity and mechanism of action of calanolide A against the human immunodeficiency virus type-1

MJ Currens, RJ Gulakowski, JM Mariner, RA Moran, RW Buckheit , KR Gustafson, JB McMahon and MR Boyd

Laboratory of Drug Discovery Research and Development, National Cancer Institute, Frederick, Cancer Research & Development Center, Maryland 21702-1201, USA.

Calanolide A, recently discovered in extracts from the tropical rainforest tree, Calophyllum lanigerum, is a novel inhibitor of the human immunodeficiency virus (HIV) type 1. The compound is essentially inactive against strains of the less common HIV type 2. The present study focused on the further characterization of the selective antiviral activity and mechanism of action of calanolide A. The compound inhibited a wide variety of laboratory strains of HIV type 1, with EC50 values ranging from 0.10 to 0.17 microM. The compound similarly inhibited promonocytotropic and lymphocytotropic isolates from patients in various stages of HIV disease, as well as drug- resistant strains. Viral life-cycle studies indicated that calanolide A acted early in the infection process, similar to the known HIV reverse transcriptase (RT) inhibitor 2', 3'-dideoxycytidine. In enzyme inhibition assays, calanolide A potently and selectively inhibited recombinant HIV type 1 RT but not cellular DNA polymerases or HIV type 2 RT within the concentration range tested. Serial passage of the virus in host cells exposed to increasing concentrations of calanolide A yielded a calanolide A resistant virus strain. RT from the resistant virus was not inhibited by calanolide A but retained sensitivity to other nonnucleoside as well as nucleoside RT inhibitors, including 3'- azido-2',3'-dideoxythymidine triphosphate and nevirapine. The study substantially supports the conclusion that calanolide A represents a novel subclass of nonnucleoside RT inhibitor which merits consideration for anti-HIV drug development.

Volume 279, Issue 2, pp. 645-651, 11/01/1996
Copyright © 1996 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				J. Auwerx, F. Rodriguez-Barrios, F. Ceccherini-Silberstein, A. San-Felix, S. Velazquez, E. De Clercq, M.-J. Camarasa, C.-F. Perno, F. Gago, and J. Balzarini The Role of Thr139 in the Human Immunodeficiency Virus Type 1 Reverse Transcriptase Sensitivity to (+)-Calanolide A Mol. Pharmacol., September 1, 2005; 68(3): 652 - 659. [Abstract] [Full Text] [PDF]

				R. W. Buckheit Jr., K. Watson, V. Fliakas-Boltz, J. Russell, T. L. Loftus, M. C. Osterling, J. A. Turpin, L. A. Pallansch, E. L. White, J.-W. Lee, et al. SJ-3366, a Unique and Highly Potent Nonnucleoside Reverse Transcriptase Inhibitor of Human Immunodeficiency Virus Type 1 (HIV-1) That Also Inhibits HIV-2 Antimicrob. Agents Chemother., February 1, 2001; 45(2): 393 - 400. [Abstract] [Full Text]

				R. W. Buckheit Jr., E. L. White, V. Fliakas-Boltz, J. Russell, T. L. Stup, T. L. Kinjerski, M. C. Osterling, A. Weigand, and J. P. Bader Unique Anti-Human Immunodeficiency Virus Activities of the Nonnucleoside Reverse Transcriptase Inhibitors Calanolide A, Costatolide, and Dihydrocostatolide Antimicrob. Agents Chemother., August 1, 1999; 43(8): 1827 - 1834. [Abstract] [Full Text]